Form 4: authID CTO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
authID Inc.'s Chief Technology Officer, Thomas Robert Szoke, reported the sale of 8,944 shares of common stock at a weighted average price of $2.93.
Summary
- Thomas Robert Szoke, Chief Technology Officer of authID Inc. (AUID), reported a transaction on September 15, 2025.
- Mr. Szoke sold 8,944 shares of authID Inc. common stock, with a par value of $0.0001 per share, at a weighted average price of $2.93 per share.
- The sale price range for these transactions was between $2.80 and $3.10.
- Following this transaction, Mr. Szoke directly beneficially owns 5,269 shares of common stock.
- Additionally, 12,500 shares are indirectly beneficially owned by Mr. Szoke's wife, Ginta Ozola-Szoke.
- The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
- Mr. Szoke also holds several stock options: 33,000 options with an exercise price of $5.35 (exercisable 06/04/2025, expiring 06/04/2035), 5,000 options at $9.25 (exercisable 12/21/2023, expiring 12/21/2033), 50,000 options at $5.48 (exercisable 06/28/2023, expiring 06/28/2033), 12,500 options at $2.64 (exercisable 03/14/2023, expiring 03/14/2033), and 4,167 options at $57.6 (exercisable 05/05/2021, expiring 05/05/2031).
- The 33,000 stock options vesting is monthly over 12 months, subject to continued service to authID Inc.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative due to an insider sale, which reduces the executive's direct stake. However, the negative impact is mitigated by the disclosure that the transaction was executed under a Rule 10b5-1 plan, indicating a pre-scheduled, rather than reactive, sale.
Positives
- The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-planned sale rather than a reaction to new negative information, which can mitigate negative market perception of insider selling.
Negatives
- An insider sale, particularly by a Chief Technology Officer, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake in the company.
Risks
- No specific risks are detailed in this Form 4 filing beyond the general market interpretation of insider transactions.
Future Outlook
This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
Insider transactions, such as sales by executives, are a routine part of the market. While a sale can sometimes be interpreted as a lack of confidence, the disclosure of a 10b5-1 plan suggests a pre-scheduled transaction, which is common for executives managing their personal finances and diversifying holdings.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Disclosure of Trading Plan | The transaction was made pursuant to a Rule 10b5-1(c) plan, which allows insiders to set up a pre-arranged plan to buy or sell company stock to avoid accusations of insider trading. | 09/15/2025 | Enhances transparency and provides a legal defense against insider trading allegations, suggesting the sale was not based on material non-public information. |
Related Party Transactions
- 12,500 shares of common stock are indirectly beneficially owned by Mr. Szoke's wife, Ginta Ozola-Szoke.
Stakeholder Impact
- Shareholders may interpret the insider sale as a signal, though the 10b5-1 plan suggests it's for personal financial management rather than a reflection of company prospects.
- Employees, particularly those holding stock options, may observe executive trading patterns as part of their assessment of company health and management confidence.
Key Dates
| Date | Description |
|---|---|
| 05/05/2021 | Date 4,167 stock options with an exercise price of $57.6 became exercisable. |
| 03/14/2023 | Date 12,500 stock options with an exercise price of $2.64 became exercisable. |
| 06/28/2023 | Date 50,000 stock options with an exercise price of $5.48 became exercisable. |
| 12/21/2023 | Date 5,000 stock options with an exercise price of $9.25 became exercisable. |
| 09/15/2025 | Date of common stock sale by Thomas Robert Szoke. |
| 06/04/2025 | Date 33,000 stock options with an exercise price of $5.35 became exercisable. |
| 05/05/2031 | Expiration date for 4,167 stock options. |
| 03/14/2033 | Expiration date for 12,500 stock options. |
| 06/28/2033 | Expiration date for 50,000 stock options. |
| 12/21/2033 | Expiration date for 5,000 stock options. |
| 06/04/2035 | Expiration date for 33,000 stock options. |
| 09/16/2025 | Signature date of the reporting person. |
Recommendation
holdWhile an insider sale by a CTO can sometimes be viewed as a negative signal, the explicit mention of a Rule 10b5-1 plan suggests this was a pre-scheduled transaction for personal financial planning rather than a reaction to new, adverse company information. Investors should consider this transaction as a data point but should not base a strong buy or sell decision solely on this Form 4 without further analysis of the company's fundamentals, market conditions, and other relevant news. Therefore, a 'hold' recommendation is appropriate, pending additional information.
Keywords
authID, AUID, insider trading, Form 4, CTO, stock sale, beneficial ownership, 10b5-1 plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.